Califia Bio Inc. is collaborating with several NIH-funded academic research groups to develop treatments for unmet therapeutic needs in the areas of neurodegenerative disease, inflammation and organ failure. Califia Bio is currently developing two series of mixed lineage kinase (MLK3) inhibitors for potential treatment of HIV-Associated Neurocognitive Disorder (HAND), Parkinson’s Disease and Heart Failure. We are exploring the development of inhibitors of dual leucine zipper kinase (DLK) as potential treatments for glaucoma and other neuropathic disorders. Califia Bio’s expertise is in hit generation, lead optimization and preclinical development. We have partnered with world-class academic biology groups to bring important discoveries to the clinic.